Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treating Residual OSA With Endotype-directed Pharmacotherapy
NCT05293600Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetazolamide, trazodone hydrochloride prolonged-release tablets, atomoxetine, eszopiclone in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Started Jul 2023; status: recruiting.
02
Drugs
acetazolamidetrazodone hydrochloride prolonged-release tabletsatomoxetineeszopiclone
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05293600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293600.